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Toward a Better Understanding of...
Defining Neuronal Subtype Specification in 
Reprogrammed Striatal Neurons
Hannah Olsen
Mentor: Andrew Yoo
The ability to reprogram human skin cells into neurons has greatly enhanced our 
understanding of human neuronal function and disease processes. We recently 
developed a protocol to reprogram human skin fibroblasts directly into striatal medium 
spiny neurons (MSNs). This class of neuronal subtype is further specified into DRD1- 
(dopamine receptor 1) or DRD2-expressing MSNs, which are differentially affected 
in Huntington’s disease (HD). In our study, ectopically expressing brain enriched 
microRNAs, miR-9/9* and miR-124 and striatum transcription factors CTIP2, DLX1/2, 
MYT1L (referenced hereafter collectively as miR-9/9*-124+CDM), converted human 
fibroblasts into MSNs comprised in the majority by DRD1-expressing cells, with 
approximately 70% of MSNs expressing DRD1. DRD2-MSNs are of great clinical 
interest as they are amongst the first cells to die in HD, with the number of DRD2-
MSNs rapidly reducing with increasing pathology severity. In addition, other studies 
have shown that the cellular expression of DRD2 mRNA is dramatically reduced in 
HD while DRD1 mRNA levels are relatively stable. Therefore, the ability to generate a 
homogenous population of DRD2-expressing MSNs from HD patients would give us an 
unprecedented platform to model HD in culture. Through a comprehensive screening of 
over 30 genes, I found the transcription factor LHX8, when transduced in conjunction 
with miR-9/9*-124+CDM, consistently produced an approximately ten-fold increase 
in transcript levels of DRD2 without affecting DRD1 expression. Similar results were 
observed in both wild type and HD cell lines, indicating that LHX8 robustly affects 
cellular fate specification independently of disease status.
